MKS Instruments (NASDAQ:MKSI – Get Free Report) will release its earnings data after the market closes on Wednesday, November 6th. Analysts expect MKS Instruments to post earnings of $1.42 per share for the quarter. MKS Instruments has set its Q3 guidance at $1.15-$1.71 EPS and its Q3 2024 guidance at 1.150-1.710 EPS.Persons interested in listening to the company’s earnings conference call can do so using this link.
MKS Instruments (NASDAQ:MKSI – Get Free Report) last announced its earnings results on Wednesday, August 7th. The scientific and technical instruments company reported $1.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.51. The firm had revenue of $887.00 million during the quarter, compared to analyst estimates of $866.38 million. MKS Instruments had a net margin of 0.25% and a return on equity of 14.91%. MKS Instruments’s revenue was down 11.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.32 EPS. On average, analysts expect MKS Instruments to post $6 EPS for the current fiscal year and $7 EPS for the next fiscal year.
MKS Instruments Stock Performance
Shares of MKSI opened at $99.57 on Tuesday. The firm has a 50-day moving average price of $107.71 and a 200 day moving average price of $119.24. The firm has a market capitalization of $6.70 billion, a PE ratio of 905.18, a P/E/G ratio of 0.70 and a beta of 1.63. The company has a quick ratio of 2.31, a current ratio of 3.58 and a debt-to-equity ratio of 2.16. MKS Instruments has a 52-week low of $67.04 and a 52-week high of $147.40.
Analyst Upgrades and Downgrades
Read Our Latest Stock Analysis on MKS Instruments
Insider Buying and Selling at MKS Instruments
In other MKS Instruments news, EVP John Edward Williams sold 1,800 shares of the company’s stock in a transaction dated Friday, August 16th. The shares were sold at an average price of $118.71, for a total transaction of $213,678.00. Following the completion of the sale, the executive vice president now directly owns 13 shares of the company’s stock, valued at approximately $1,543.23. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Elizabeth Mora sold 275 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $115.97, for a total value of $31,891.75. Following the completion of the sale, the director now directly owns 17,934 shares of the company’s stock, valued at $2,079,805.98. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP John Edward Williams sold 1,800 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $118.71, for a total transaction of $213,678.00. Following the completion of the sale, the executive vice president now directly owns 13 shares of the company’s stock, valued at $1,543.23. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,325 shares of company stock valued at $272,795. 0.46% of the stock is currently owned by corporate insiders.
MKS Instruments Company Profile
MKS Instruments, Inc provides foundational technology solutions to semiconductor manufacturing, electronics and packaging, and specialty industrial applications in the United States, Germany, China, South Korea, and internationally. It operates through Vacuum Solutions Division (VSD), Photonics Solutions Division (PSD), and Material Solutions Division (MSD) segments.
See Also
- Five stocks we like better than MKS Instruments
- The 3 Best Retail Stocks to Shop for in August
- Intel: Is Now the Time to Be Brave?Â
- What Are Dividend Achievers? An Introduction
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What Are Dividend Contenders? Investing in Dividend Contenders
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for MKS Instruments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MKS Instruments and related companies with MarketBeat.com's FREE daily email newsletter.